Next generation biopharmaceuticals

About Affibody

Affibody is a clinical stage biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod®.

The company operates a focused experimental medicine model and currently has two clinical stage programs. The first is izokibep that targets autoimmune diseases. The second program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

Affibody has ongoing commercial relationships with several companies such as AbClon, Biotest, Daewoong, GE Healthcare, Inmagene, and Rally Bio.

Affibody AB is a holding of Patricia Industries.

”Our mission is to improve the lives of patients with serious diseases by being a research-driven company with a long term commitment to development of proteinbased drugs”

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Interim Report January to March 2020 (May 15, 2020)
  • Interim Report January to June 2020 (August 21, 2020)
  • Interim Report January to September 2020 (November 13, 2020)
  • Year End Report 2020 (February 2021)